CrossAssetDataThe Company File
···
SHC

Sotera Health Company

Sotera Health Company is classed by the SEC under Services-Misc Health & Allied Services, NEC (industry code 8090), based in Broadview Heights, OH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.2 billion and a profit of $78 million (its filed statements).

Usage business Services-Misc Health & Allied Services, NEC Broadview Heights, OH filings since 2020 9 of 9 filed
Ask the desk about SHC → Compare SHC with AGL → Price chart on TradingView ↗ Full EDGAR file ↗ Watch SHC →

Sector peers: AGLPGNYDVAVMD

5.6/10headline grade
vs its business-model standard
6.2/10past 5.2/10present 5.4/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8090, Services-Misc Health & Allied Services, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.6 out of ten, 9 of 9 metrics filed: past 6.2 out of ten, present 5.2 out of ten, future 5.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2020. 82nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 6.5 out of ten. +6.9% a year over 7 filed years; profitable in 4 of 7. 65th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 2.7 out of ten. Share count grew 0.7% a year. 0% of cash flow returned. Insiders: 18 sales, 0 purchases. 27th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.5 out of ten. ROE 13%: 13¢ of profit per shareholder dollar. Leverage 81%: owes 81¢ per asset dollar. 55th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.0 out of ten. top 40% of 10 in its family; net margin 6.7%. 60th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 3.1 out of ten. bottom 31% of 7 in its family for leadership; chief executive since 2026. 31st percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 4.2 out of ten. bottom 42% of 10 in its family for room to expand. 42nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.5 out of ten. bottom 45% of 10 in its family for growth drivers. 45th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 7.5 out of ten. top 25% of 10 in its family for expectations against reality. 75th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-09. Filings on record since 2020. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2025: Sterigenics 65%, Nelson Labs 19%, Nordion 16%. By geography: United States 54%, Europe 20%, Canada 19%, Other 7%. As tagged in its annual report (Form 10-K, filed 2026-02-24).

Who runs it

Shader, Alton (Chief Executive Officer); Petras, Michael B. Jr. (Executive Chairman); Rutz, Michael P (President of Sterigenics); Lyons, Jonathan M. (Sr. Vice President, CFO); Ostrowski, Erika (SVP, General Counsel and Sec.); Dimitrief, Alexander (Former SVP, GC and Sec.); Chen, Ruoxi (director); Cunningham, Sean Laurence (director); Flynn, Karen (director); Klee, Ann R. (director); and 28 more. 38 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.